About us

ABOUT US

About us

In a nutshell

Da Volterra is a clinical-stage biopharmaceutical company which innovates for better health and care for people worldwide.

Our team is composed of 35 people with an extensive experience in science and in the industrial development of medical products. Together, we are dedicated to developing novel and safe therapeutic options for patients.

Our expertise focuses on the protection of the intestinal microbiota during antibiotic treatments.

  • Based in Paris,
    France
  • 35 collaborators,
    14 PhD
  • Total funds raised since
    inception: 57M€
  • 1 product in phase 2
    clinical trial

Our goal

Da Volterra’s goal is to develop and commercialize innovative healthcare solutions to preserve the intestinal microbiota of patients worldwide and help prevent and cure life-threatening diseases.

As new insights into the human intestinal microbiota are fundamentally reshaping how we understand and treat a wide range of diseases, Da Volterra is a pioneer in understanding and harnessing the microbiota capacity to help prevent and cure diseases.

The company’s most advanced product is DAV132, an oral product to be co-administered with any antibiotics, in order to protect patients from antibiotic-induced intestinal microbiota disruption.

History

The company was created by Professor Antoine Andremont whose life-long research was dedicated to antibiotic resistance and understanding the impact of antibiotics on the intestinal microbiota.

2000

Company inception

Prof. Antoine Andremont creates Da Volterra based on concepts originating from his work on the impact of antibiotics on the intestinal microbiota and antibiotic resistance. Academic collaborations are set-up to explore early research work.

2006

Early technology patent filling

The first patents are granted on innovative approaches to protect the intestinal microbiota and spare patients from life-threatening bacterial infections. Further innovations are developed later on with new patent applications filed regularly by the R&D team.

2009

Company structuration

The team is building up and takes foot in its facilities and laboratories of the Rue de Charonne in Paris.
10 employees are recruited.

2014

DAV132 proof of concept

The proof-of-concept of DAV132 is achieved in humans under an antibiotic treatment:
– No interaction with antibiotic efficacy
– Free antibiotic faecal concentrations decreased by 99%
– A very good protection of the microbiota diversity is achieved

2015

DAV132 reaches regulatory milestones

CE mark granted in Europe and Pre-IND meeting with FDA clears the development path as a drug in the USA.

2018

Phase 2 trial for DAV132

SHIELD study is the first DAV132 phase 2 clinical trial in patients in Europe assessing product safety, prevention of CDI and protection of the intestinal microbiota.

SHIELD stands for European multicenter, randomized, parallel-groups study to evaluate the Safety and efficacy/Performance of DAV132 in hospitalized patients at HIgh risk for CLostridium difficile Infection And who receive fluoroquinolones for the treatment of acute Infections.